Effect of Exercise Training on Plasma Levels and Functional Properties of High-Density Lipoprotein Cholesterol in the Metabolic Syndrome

Antonio Casella-Filho, MD, MSc, PhD[a],*, Antonio Carlos P. Chagas, MD, PhD[a],
Raul C. Maranhão, MD, PhD[a], Ivani C. Trombetta, PhD[a], Fernando H. Y. Cesena, MD, PhD[a],
Vanessa M. Silva, PhD[a], Jose Eduardo Tanus-Santos, MD, PhD[b], Carlos E. Negrão, PhD[a], and
Protasio L. da Luz, MD, PhD[a]

Intense lifestyle modifications can change the high-density lipoprotein (HDL) cholesterol concentration. The aim of the present study was to analyze the early effects of short-term exercise training, without any specific diet, on the HDL cholesterol plasma levels and HDL functional characteristics in patients with the metabolic syndrome (MS). We studied 30 sedentary subjects, 20 with and 10 without the MS. The patients with the MS underwent moderate intensity exercise training for 3 months on bicycle ergometers. Blood was sampled before and after training for biochemical analysis, paraoxonase-1 activity, and HDL subfraction composition and antioxidative capacity. Lipid transfer to HDL was assayed in vitro using a labeled nanoemulsion as the lipid donor. At baseline, the MS group had greater triglyceride levels and a lower HDL cholesterol concentration and lower paraoxonase-1 activity than did the controls. Training decreased the plasma triglycerides but did not change the low-density lipoprotein or HDL cholesterol levels. Nonetheless, exercise training increased the HDL subfractions' antioxidative capacity and paraoxonase-1 activity. After training, the MS group had compositional changes in the smallest HDL subfractions associated with increased free cholesterol and cholesterol ester transfers to HDL, reaching normal values. In conclusion, the present investigation has added relevant information about the dissociation between the quantitative and qualitative aspects of HDL after short-term exercise training without any specific diet in those with the MS, highlighting the importance of evaluating the functional aspects of the lipoproteins, in addition to their plasma levels. © 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1168–1172)

We investigated the changes in high-density lipoprotein (HDL) cholesterol plasma levels and in the HDL functional characteristics induced by short-term exercise training in patients with the metabolic syndrome (MS).

Specifically, we investigated the changes in HDL composition, antioxidative capacity, and ability to accept lipids. To focus on exercise effects and thus avoid interference from other variables such as dietary modifications, the participants did not receive any specific nutritional counseling.

Methods

The ethics committee of the University of São Paulo Medical School approved the present investigation, and all participants provided written informed consent. The study cohort included 30 subjects (10 healthy controls and 20 with the MS) selected from the outpatient clinic of the Heart Institute, Hospital das Clínicas of the University of São Paulo Medical School. Their age range was 21 to 70 years, and they were nonsmokers and abstainers or only moderate alcohol consumers (<25 g/day). None had cardiovascular, renal, liver, gastrointestinal, pulmonary, endocrine, or oncologic diseases. None was receiving antioxidant vitamin supplementation or drugs known to affect lipoprotein metabolism.

The presence of the MS was defined according to the American Heart Association/National Heart, Lung, and Blood Institute scientific statement.[1] The criteria for the clinical diagnosis of the MS was the presence of ≥3 of the following characteristics: elevated waist circumference (≥102 cm in men and ≥88 cm in women), elevated triglycerides (TG) (≥150 mg/dl) or receiving drug treatment for elevated TG, reduced HDL cholesterol (≤40 mg/dl in men, ≤50 mg/dl in women) or receiving medication for reduced HDL cholesterol, elevated blood pressure (≥130 mm Hg systolic blood pressure or ≥85 mm Hg diastolic blood pressure) or receiving antihypertensive drug treatment with a history of hypertension, elevated fasting glucose (≥100 mg/dl) or receiving medication for elevated glucose.

Patients with the MS underwent exercise training for 3 months. A bicycle cardiopulmonary exercise test was performed by healthy controls at baseline and by the MS group at baseline and after the 3-month exercise period. The peak oxygen uptake was considered at the end of the test (ramp protocol with 10- to 15-W increments every minute until exhaustion) when the subject no longer maintained the bicycle velocity at 60 rpm.[2] The heart rates corresponding to the anaerobic threshold and the respiratory compensation point were determined. The training program consisted of a 3-times/week supervised and controlled training load (45 min/day) on a bicycle ergometer, as previously described.[3,4] The exercise was considered of moderate intensity and compared to brisk walking. The participants began their training at the heart rate corresponding to the anaerobic threshold. The exercise was then progressively intensified, according to each patient's subjective effort perception, up to the heart rate corresponding to 10% less than the respiratory compensation point.

Blood samples were obtained after the patient had fasted for ≥12 hours, always at the same point of the menstrual cycle in the women, and ≥16 hours after the last exercise session. The total cholesterol (TC), HDL cholesterol, TG, and plasma glucose levels were measured using commercially available kits and standardized techniques. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula.[5]

Apolipoprotein A-I was determined using a commercial kit (Wako Pure Chemical, Osaka, Japan), and the serum samples were assayed for paraoxonase-1 activity using paraoxon as a substrate, as previously described.[6]

The preparation of a lipidic nanoemulsion labeled with ^{14}C-phospholipid, ^{3}H-triglycerides, ^{14}C-cholesterol, or ^{3}H-cholesteryl ester (all from Amersham International, Amersham, United Kingdom) was performed, as previously described.[7,8] The incubation of the radioactive nanoemulsion with the patient's whole plasma, the chemical precipitation of the apolipoprotein B-containing lipoproteins and the nanoemulsion, and the measurements of the radioactivity transferred from the nanoemulsion to the supernatant containing the HDL fraction were performed as previously described.[9] Venous blood collected in tubes containing ethylenediaminetetraacetic acid was kept on ice and immediately centrifuged at 4°C. The plasma was then mixed with sucrose (final concentration 0.6% wt/vol) as a cryoprotectant for lipoproteins[10] and frozen at −80°C in plastic cryovials.

LDL and HDL were fractionated using 2 different methods. LDL was isolated using an adaptation of the single vertical spin discontinuous density gradient ultracentrifugation method.[11] In brief, the plasma density was adjusted to 1.400 kg/L by the addition of solid potassium bromide. This solution was then overlaid with saline and ultracentrifuged for 120 minutes at 70,000 rpm at 4°C. The LDL was then removed by aspiration of the orange band from the top of the tube. HDL was fractionated using single spin isopycnic density gradient ultracentrifugation.[12] Five major HDL subfractions were obtained: large, light HDL2b and HDL2a and small, dense HDL3a, HDL3b, and HDL3c. The lipoproteins were stored at 4°C and used within 10 days. Before being used in the experiments, ethylenediaminetetraacetic acid

and potassium bromide were removed from the LDL and HDL solutions by exhaustive dialysis with phosphate-buffered saline and Chelex 100 (Bio-Rad Laboratories, California) for 24 hours at 4°C, with the buffer changed 3 times.

The content of protein, TC, and TG in the HDL subfractions was analyzed using commercially available kits and standardized techniques. Free cholesterol and phospholipids were determined using commercial kits (Wako Pure Chemical, Osaka, Japan), and the cholesterol ester content was calculated by the difference between the TC and free cholesterol.

The oxidizability of a reference LDL, retrieved from a control subject and used throughout the study, was analyzed by the in vitro resistance to oxidation with copper sulfate, using standardized methods.[13] The antioxidative activities of the HDL subfractions were evaluated by the influence of the HDL subfractions on the resistance of the reference LDL to oxidation with copper sulfate, slightly modified, as described previously.[14] In brief, the reference LDL (100 μg of protein/ml) was incubated at 37°C in phosphate-buffered saline in the presence of copper sulfate (5 μm) for 4 hours. The accumulation of conjugated dienes was continuously measured as the increment in absorbance at 234 nm. Two characteristic phases were identified: the lag phase and the propagation phase. Individual HDL subfractions (80 μg of protein/ml) were added to the LDL directly before oxidation. We used the HDL2a and HDL3b subfractions as representatives of HDL2 and HDL3. HDL2a was obtained from the patients with the MS before and after the exercise training, was co-incubated with the reference LDL, and the resistance to oxidation with copper sulfate was evaluated. The percentage of variation in the lag phase time for oxidation (after vs before training) was determined. The same procedure was performed with HDL3b.

Statistical analyses were performed using the Statistical Package for Social Sciences for Windows, version 10 (SPSS, Chicago, Illinois). All values are expressed as the mean ± SD, unless otherwise indicated. An α probability of $p < 0.05$ was required for statistical significance. Between-group differences in the continuous variables were analyzed using the Student t test or Wilcoxon nonparametric test for dependent samples, as applicable. The chi-square test was used to compare the proportions between the controls and the MS group.

Results

Compared to the controls, the MS group had a greater body mass index (32.4 ± 3.3 vs 24.3 ± 2.6 kg/m^2, $p < 0.05$), waist circumference (110 ± 10 vs 88 ± 7 cm, $p < 0.05$), blood pressure ($141 \pm 10/92 \pm 4$ vs $120 \pm 6/75 \pm 5$ mm Hg, $p < 0.05$), TC (203 ± 20 vs 192 ± 25 mg/dl, $p < 0.05$), LDL cholesterol (123 ± 21 vs 116 ± 22 mg/dl, $p < 0.05$), and plasma glucose (112 ± 19 vs 81 ± 6 mg/dl, $p < 0.05$).

The effectiveness of exercise training in the MS group was demonstrated by an approximately 20% increase in the peak oxygen uptake on the cardiopulmonary test (from 19.9 ± 4.3 to 23.7 ± 4.6 ml/kg min, $p < 0.05$). Exercise did not affect the body mass index (32.4 ± 3.3 vs 32.4 ± 3.2 kg/m^2 before and after training, respectively, $p > 0.05$) but

Table 1
Individual data on plasma lipids and transfer of labeled lipids to HDL of study subjects, before and after training

Pt. No.	Gender	Age (years)	Lipid Concentration (mg/dl)				Transfer of Labeled Lipids to HDL (%)							
			HDL Cholesterol		TG		^{14}C-PL		^{3}H-TG		^{14}C-C		^{3}H-CE	
			Before	After	Before	After	Before	After	Before	After	Before	After	Before	After
MS														
1	Female	45	40	39	157	154	21.4	27.2	4.3	3	10	9.3	4.1	3.9
2	Female	58	41	41	193	208	21.5	25.9	3.4	3.1	8.1	8.6	3.4	4
3	Female	29	34	36	230	210	22.8	26.7	4.4	3.4	8.8	8.4	4.1	5.4
4	Female	49	41	44	177	179	28.2	25.3	3.7	2.8	7	7.7	2.4	3.6
5	Female	61	40	39	282	234	30.3	26.1	3.4	3.3	8.1	8.6	3.3	4.1
6	Female	54	40	43	326	111	27.9	27.1	4.8	2.7	8.1	7.8	2.5	4
7	Female	49	49	53	162	91	25.2	26.4	3.1	2.7	8	8.5	2.4	4.2
8	Female	42	39	34	230	213	25.4	25.7	3.2	4.3	7.8	8.3	2.3	3.3
9	Female	57	34	30	370	330	29.4	26.2	3	5.4	7.5	7.6	2.1	3.4
10	Female	56	40	36	276	191	27.4	25.6	3.2	4.5	8.7	8.9	2.9	2.8
11	Male	69	34	37	155	95	25	25.3	3.8	6.1	8.6	10.1	6.9	3.1
12	Male	47	31	34	159	156	32.2	24.7	4.6	5.5	8.5	8.9	3.3	3.7
13	Male	57	26	27	273	270	26	23.2	4.4	5.1	6.4	7.1	4.1	4.7
14	Male	40	35	27	166	104	30.3	24.9	3.4	3.3	7	8.3	3.3	4.1
15	Male	56	32	43	164	98	28.2	24.8	3.7	2.8	7.4	7.7	2.4	3.5
16	Male	50	36	37	265	200	26	23.2	4.4	5.1	6.1	7.1	4.1	4.2
17	Male	52	31	31	233	301	25.4	25.7	3.2	4.3	7.8	8.3	2.3	3.3
18	Male	47	36	44	195	206	32.2	25.8	4.6	5.5	7.7	8.6	3.3	3.7
19	Male	31	33	34	139	129	23.7	23.7	3.3	5.2	8.6	7.5	2.1	3.4
20	Male	55	37	40	195	192	30.2	26.5	4.4	2.9	6.8	9.1	4.4	4.5
Mean ± SD		50 ± 10*	36 ± 5†	37 ± 6†	217 ± 64†	184 ± 68†‡	26.9 ± 3.2*	25.5 ± 1.2*	3.8 ± 0.6†	4.1 ± 1.2†	7.9 ± 0.9†	8.3 ± 0.8*‡	3.3 ± 1.1†	3.8 ± 0.6*‡
Controls														
1	Female	41	51		73		31.1		6.4		7		4.8	
2	Female	43	60		114		27		6.6		9.3		4.1	
3	Female	37	56		75		24.6		4.8		7		3.6	
4	Female	43	47		146		28		6.1		9.8		5	
5	Male	46	57		150		27.4		8.3		10.3		3.4	
6	Male	46	48		148		28.6		6.4		9.4		3.2	
7	Male	63	43		146		23.9		6.1		9.3		4.6	
8	Male	42	44		142		24.2		7.1		10.5		5.3	
9	Male	44	69		128		27.1		8.5		9.7		5.5	
10	Male	45	47		76		25.4		6.9		6.9		4.1	
Mean ± SD		45 ± 7	52 ± 8		120 ± 33		26.7 ± 2.3		6.7 ± 1.1		8.9 ± 1.4		4.4 ± 0.8	

* p >0.05 versus control; † p <0.05 versus control; ‡ p <0.05 versus before training.

Pt. No. = patient number; ^{14}C-C = ^{14}C-cholesterol; ^{14}C-PL = ^{14}C-phospholipid; ^{3}H-CE = ^{3}H-cholesteryl ester; ^{3}H-TG = ^{3}H-triglycerides.

Figure 1. (*A*) Percentage of increase in LDL resistance to oxidation with addition of HDL2a or HDL3b subfractions from the MS group before and after 3 months of exercise training (Tr). Bars indicate mean ± SEM. (*B*) Paraoxonase-1 (PON1) activity in controls and patients with the MS before and after 3 months of exercise training (Tr). Bars indicate mean ± SEM.

did reduce the waist circumference (from 110 ± 10 to 107 ± 9 cm, $p < 0.05$) and blood pressure (from $141 \pm 10/92 \pm 4$ to $135 \pm 7/89 \pm 5$ mm Hg, $p < 0.05$).

Exercise training did not significantly change the HDL cholesterol (Table 1), TC (203 ± 20 vs 196 ± 27 mg/dl before and after training, respectively, $p > 0.05$), LDL cholesterol (123 ± 21 vs 122 ± 27 mg/dl before and after training, respectively, $p > 0.05$), or apolipoprotein A-I (1.43 ± 0.25 vs 1.45 ± 0.21 g/L before and after training, respectively, $p > 0.05$) plasma levels. However, a significant increase occurred in the LDL resistance to oxidation with the addition of HDL2a or HDL3b subfraction from the MS group after training compared to the addition of the respective HDL2a or HDL3b subfraction before training (Figure 1).

Consistently, a significant increase occurred in the serum paraoxonase-1 activity in patients with the MS after training, although the final values remained lower than those in the healthy subjects (Figure 1).

These effects were associated with no difference in the protein or phospholipid contents in all HDL subfractions but with a trend toward a decrease in free cholesterol in HDL3b ($p = 0.06$) and HDL3c ($p = 0.06$). A decrease was found in the TC and TG contents in HDL3b (-7.3% and -12.3%, respectively, $p < 0.05$) and HDL3c (-13.2% and -15.1%, respectively, $p < 0.05$) and an increase in cholesterol ester content in HDL3b ($+8.2\%$, $p < 0.05$) and a trend toward an increase in HDL3a ($p = 0.06$) and HDL3c ($p = 0.06$).

The results of the lipid transfer process from lipidic nanoemulsion labeled with radioactive lipids to plasma HDL particles are listed in Table 1. At baseline, the patients with the MS had a lower transfer of ^{3}H-triglycerides, ^{14}C-cholesterol, and ^{3}H-cholesteryl ester than did the controls, but ^{14}C-phospholipid transfer was similar between the 2 groups. After training, an increase was found in the ability of HDL particles to accept free cholesterol and cholesterol ester from lipidic nanoemulsion in the MS group (both $p < 0.05$), reaching values similar to those obtained in the control subjects. The phospholipid transfer did not change. A trend was seen toward an increase in TG transfer after training in the MS group, although the final values were lower than those from the control group.

Discussion

The main finding of the present study was the dissociation between the functional improvement in the qualitative aspects of HDL, with no significant changes in the plasma levels of HDL cholesterol in patients with the MS, after a controlled 3-month aerobic exercise training program, in the absence of any specific nutritional counseling. Functional changes in HDL seemed to occur earlier than, and independent from, the increase in HDL cholesterol levels when the patients with the MS started an aerobic exercise program.

HDL-based therapies have long been focused on increasing the plasma HDL cholesterol levels.[15,16] In recent years, attention has expanded to how different therapeutic strategies affect HDL function, which might be as important as, or even more relevant than, the HDL cholesterol levels in modifying cardiovascular risk.[17] The assumption that the serum concentration of HDL cholesterol only partially depicts the cardiovascular risk of this lipoprotein has been supported by our results.

Previous studies have showed that the antioxidative capacity of the smaller, denser HDL subfractions in protecting LDL from oxidation is impaired in patients with the MS and that those dysfunctional HDL subfractions are associated with elevated oxidative stress.[18] The present investigation has added relevant information, showing that this functional impairment of HDL can be offset early by short-term exercise per se (without any specific diet), with an association with an increase in paraoxonase-1 activity.

We hypothesized that this change in HDL antioxidative property is closely related to the changes in HDL lipid content. Alterations in lipid transfer conceivably change HDL composition and thereby the binding or the activity of enzymes and other proteins adhered to the lipoprotein surface, such as paraoxonase-1. The effects of exercise training in correcting the alterations of lipid transfers and paraoxonase-1 activity of those with the MS were remarkable, especially because the HDL cholesterol levels remained unchanged. As the transfer of free cholesterol and cholesterol ester increased with training, paraoxonase-1 activity also increased, possibly owing to compositional changes more favorable to enzyme function.

The antioxidant activity of the HDL subfractions HDL2a and HDL3b also increased, an effect that also could be ascribed to the exercise-induced lipid transfer enhancement and to the consequent compositional changes. Also, post-

training compositional changes were noted in HDL3b and HDL3c.

Our results are consistent with the findings from other studies[19,20] that showed that a 4-month training program in patients with diabetes mellitus and intensive lifestyle modifications in overweight/obese men, including dietary intervention with weight loss, improved some HDL functional characteristics and enhanced the HDL anti-inflammatory properties. However, the participants in our study did not receive any nutritional counseling, implying that the results should be solely attributed to the implementation of the 3-month physical activity program, with minimal or no influence from changes in food intake. Within this context, it is worthwhile to note that, in actuality, many patients do not follow the medical counseling of diet and exercise simultaneously.

All these findings indicate that the interference of non-pharmacologic interventions on HDL metabolism goes beyond, and is not accurately reflected by, the plasma HDL cholesterol levels, highlighting the importance of evaluating the functional aspects of the lipoproteins, in addition to their plasma levels.

1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific statement. *Circulation* 2005;112:2735–2752.

2. Wasserman K, Whipp BJ, Koyl SN, Beaver WL. Anaerobic threshold and respiratory gas exchange during exercise. *J Appl Physiol* 1973; 35:236–243.

3. Trombetta IC, Batalha LT, Rondon MU, Laterza MC, Kuniyoshi FH, Gowdak MM, Barretto AC, Halpern A, Villares SM, Negrão CE. Weight loss improves neurovascular and muscle metaboreflex control in obesity. *Am J Physiol Heart Circ Physiol* 2003;285:H974–H982.

4. American College of Sports Medicine. ACMS's Guidelines for Exercise Testing and Prescription. 7th ed. Philadelphia: Lippincott, Williams & Williams; 2007.

5. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499–502.

6. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. *Atherosclerosis* 1991;86:193–199.

7. Giribela AH, Melo NR, Latrilha MC, Baracat EC, Maranhão RC. HDL concentration, lipid transfer to HDL, and HDL size in normolipidemic nonobese menopausal women. *Int J Gynecol Obstet* 2009;104:117–120.

8. Daminelli EN, Spada C, Treitinger A, Oliveira TV, Latrilha Mda C, Maranhão RC. Alterations in lipid transfer to high-density lipoprotein (HDL) and activity of paraoxonase-1 in HIV+ patients. *Rev Inst Med Trop Sao Paulo* 2008;50:223–227.

9. Lo Prete AC, Dina CH, Azevedo CH, Puk CG, Lopes NH, Hueb WA, Maranhão RC. In vitro simultaneous transfer of lipids to HDL in coronary artery disease and in statin treatment. *Lipids* 2009;44:917–924.

10. Rumsey SC, Stucchi AF, Nicolosi RJ, Ginsberg HN, Ramakrishnan R, Deckelbaum RJ. Human plasma LDL cryopreserved with sucrose maintains in vivo kinetics indistinguishable from freshly isolated human LDL in cynomolgus monkeys. *J Lipid Res* 1994;35:1592–1598.

11. Chung BH, Segrest JP, Ray MJ, Brunzell JD, Hokanson JE, Krauss RM, Beaudrie K, Cone JT. Single vertical spin density gradient ultracentrifugation. *Methods Enzymol* 1986;128:181–209.

12. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. *J Lipid Res* 1981;22:339–358.

13. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. *Free Radic Res Commun* 1989;6:67–75.

14. Nobécourt E, Jacqueminet S, Hansel B, Chantepie S, Grimaldi A, Chapman MJ, Kontush A. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. *Diabetologia* 2005;48:529–538.

15. Sacks FM; Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. *Am J Cardiol* 2002;90:139–143.

16. Hausenloy DJ, Yellon DM. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. *Curr Opin Cardiol* 2009;24:473–482.

17. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. *J Am Coll Cardiol* 2008; 51:2199–2211.

18. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, Kontush A. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. *J Clin Endocrinol Metab* 2004;89:4963–4971.

19. Roberts CK, Ng C, Hama S, Eliseo AJ, Barnard RJ. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. *J Appl Physiol* 2006;101:1727–1732.

20. Ribeiro IC, Iborra RT, Neves MQ, Lottenberg SA, Charf AM, Nunes VS, Negrão CE, Nakandakare ER, Quintão EC, Passarelli M. HDL atheroprotection by aerobic exercise training in type 2 diabetes mellitus. *Med Sci Sports Exerc* 2008;40:779–786.